Anti-TNF alpha therapy: An immunological analysis of risk factors and side effects;Risiken und nebenwirkungsreaktionen unter einer therapie mit TNF alpha-blockern: Eine immunologische analyse

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 30, 2004, Pages 1631-1634

  Berg, P A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; SEMAPIMOD; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPERGILLOSIS; AUTOIMMUNITY; CANDIDIASIS; CLINICAL IMMUNOLOGY; CROHN DISEASE; DRUG HYPERSENSITIVITY; EXTRAPULMONARY TUBERCULOSIS; HEMOSTASIS; HISTOPLASMOSIS; HUMAN; LISTERIOSIS; NONHODGKIN LYMPHOMA; PNEUMOCYSTOSIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SEPSIS; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; CROHN DISEASE; HOMEOSTASIS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3242878883     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829005     Document Type: Article

References (47)

1. Bekanntmachungen der Kassenärztlichen Bundesvereinigung: Therapiehinweis nach Nr. 14 Arzneimittel-Richtlinien: Infliximab bei rheumatoider Arthritis (z.B. Remicade®). Dtsch Ärzteblatt 2002; 99: C2238-C2239
2. Adorini L. Cytokine-based immunointervention in the treatment of autoimmune diseases. Clin Exp Immunol 2003; 132: 185-192
3. Andus T, Stanger EF, Höffler D, Keller-Stanislawski B. Verdachtsfälle schwerwiegender Nebenwirkungen nach Infliximab (Remicade®) aus Deutschland. Med Klin 2003; 98: 429-436
4. Armitage RL. Tumor necrosis receptor superfamily members and their ligands. Curr Opin Immunol 1994; 6: 407-413
5. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998; 17: 3261-3270
6. Bernik TR, Friedman SG, Ochani M et al. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med 2002; 195: 781-788
7. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2003; 48: 2389
8. Butler DM, Malfait AM, Mason LJ et al. DBA/1 mice expressing the human TNF(-transgene develop a severe erosive arthritis. J Immunol 1997; 159: 2867-2876
9. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF-Therapy against congestive heart failure investigators. Circulation 2003; 107: 3133-3140
10. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420: 885-891
11. Colombel JF, Jr. Loftus EV, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31
12. Feldman AM, McTiernan C. Is there any future for tumor necrosis factor antagonists in chronic heart failure? Am J Cardiovasc Drugs 2004; 4: 11-19
13. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nature reviews 2002; 2: 364-371
14. Fleischmann R, Igbal I, Nandeshwar P, Quiceno A. Safety and efficacy of disease modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Safety 2002; 25: 173-197
15. Flynn JL, Golstein MM, Chan J et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobaterium tubrculosis in mice. Immunity 1995; 2: 561-572
16. Garcia-Planella E, Domènech E, Esteve-Comas M et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNF(antibodies (infliximab). Eur J Gastroenterol Hepatol 2003; 15: 351-354
17. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-798
18. Ghezzi P, Mennini T. Tumor necrosis factor and motoneuronal degeneration: an open problem. Neuroimmunomodulation 2001; 9: 178-182
19. Glück T, Linde HJ, Schölmerich J, Müller-Ladner U, Fiehn C, Boland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 2002; 46: 2255-2257
20. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montera MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 2003; 48: 2122-2127
21. Haas HS, Schauenstein K. Neuroimmunomodulation via limbic structures - the neuroanatomy of psychoimmunology. Prog Neurobiol 1997; 51: 195-222
22. Hamilton CD. Tuberculosis in the cytokine era: What rheumatologists need to know. Arthritis Rheum 2003; 438: 2085-2091
23. Hibi T, Inoue N, Ogata H, Naganuma M. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. J Gastroenterol 2003; 38: 36-42
24. Hommes D, Van den Blink B, Plasse T et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002; 122: 7-14
25. Keane J, Gershon S, Pharm D et al. Tuberculosis associated with infliximab, a tumor necrosis factor (α-neutralizing agent. N Engl J Med 2001; 345: 1098-1104
26. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 2003; 9: 176-178
27. Klareskog L, McDevitt H. Rheumatoid arthritis and its animal models: the role of TNF-( and the possible absence of specific immune reactions. Current Opinion Immunology 1999; 11: 657-662
28. Krakauer T, Vilcek J, Oppenheim JJ. Proinflammatory cytokines: TNF and IL-1 families, chemokines, TGF-β, and others. 4th ed (Hrsg). Lippincott-Raven Publishers, Philadelphia, New York, In: Paul WE: Fundamental Immunology. 1999: 775-829
29. Lamprecht P, Arbach O, Voswinkel J et al. Remissionsinduktion mit Infliximab bei therapierefraktärer Wegenerscher Granulomatose - Verlaufsbeobachtung. Dtsch Med Wochenschr 2002; 127: 1876
30. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563
31. Mann DI. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988-998
32. Mikuls TR, Moveland LW. Benefit-rich assessment of inflixiMoAb in the treatment of rheumatoid arthritis. Drug Safety 2003; 26: 23-32
33. Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-2869
34. Roach DR, Bean AGD, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168: 4620-4627
35. Rook GAW, Lightman SL, Heijnen CJ. Can nerve damage disrupt neuroendocrine immune homeostasis? Leprosy as a case in point. Trends Immunol 2002; 23: 18-22
36. Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology 2003; 124: 1140-1144
37. Sandor M, Weinstock JV, Wynn TA. Granulomas in schistosome and mycobacterial infections: a model of local immune responses. Trends Immunol 2003; 24: 44-52
38. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-580
39. Stockes DG, Kremer JM. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum 2003; 33: 1-18
40. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206-211
41. Jr. Thomas CW, Weinshenker BG, Sandborn WJ. Demyelination during anti-tumor necrosis factor α therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004; 10: 28-31
42. Tomasdottir H, Hjartarson H, Ricksten A, Wasslavik C, Bengtsson A, Ricksten SE. Tumor necrosis factor gene polymorphism is associated with enhanced systemic inflammatory response and increased cardiopulmonary morbidity after cardiac surgery. Anesth Analg 2003; 97: 944-949
43. van den Brande JMH, Braat H, van den Brink GR et al. Infliximab but not Etanercept induces apoptosis in lamina propria T-lymphozytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-1785
44. Vermeire S, Noman M, van Assche G et al. Autoimmunity associated with antitumor necrosis factor α treatment in Crohn's disease: a prospektive cohort study. Gastroenterology 2003; 125: 32-39
45. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259
46. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid aarthritis in patients taking concomitant methotrexate. Arthritis Rheum 2003; 48: 35-45
47. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 327-329